Clinical Trial

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Study acronym: NeoTurbo
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2025 (before its estimated March 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-04-15; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-03-18
Trial Details
NCT Number NCT05340270
Lead Sponsor Guangxi Medical University
Collaborators: Hainan People's Hospital, Wuzhou Red Cross Hospital, First People's Hospital of Yulin, Fourth Affiliated Hospital of Guangxi Medical University, Guigang People's Hospital, LiuZhou People's Hospital, Affiliated Hospital of North Sichuan Medical College
Conditions Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
Enrollment 150 participants
Start Date 2022-07-15
Primary Completion 2026-03-29 (estimated)
Study Completion 2029-03-29 (estimated)
Updated on ClinicalTrials.gov 2025-12-11